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Abstract
Study Objective: As variability in vancomycin dosing, susceptibility, and tolerability has driven
the need to compare newer agents with vancomycin in real-world clinical settings, we sought to
quantify the effectiveness of linezolid compared with vancomycin on clinical outcomes for the
treatment of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia.
Design: Retrospective cohort study.
Data Source: Veterans Health Administration national databases.
Patients: Adults admitted to Veterans Affairs hospitals between January 2002 and September
2010 with diagnosis codes for MRSA and pneumonia, and who initiated and received at least 3
days of continuous intravenous vancomycin therapy (4943 patients) or intravenous or oral
linezolid therapy (328 patients) while in the hospital.
Measurements and Main Results: Propensity score–adjusted Cox proportional hazards
regression models quantified the effect of linezolid compared with vancomycin on time to 30-day
mortality (primary outcome), therapy change, hospital discharge, discharge from intensive care,
intubation, 30-day readmission, and 30-day MRSA reinfection. In addition, a composite outcome
of clinical success was defined as discharge from the hospital or intensive care unit by day 14
after treatment initiation, in the absence of death, therapy change, or intubation by day 14.
Subgroup analyses were performed in a validated microbiology-confirmed MRSA subgroup and
clinical subgroup meeting clinical criteria for infection. Although a number of baseline variables
differed significantly between the vancomycin and linezolid treatment groups, balance was
achieved within propensity score quintiles. A significantly lower rate of therapy change was
observed in the linezolid group (adjusted hazard ratio [HR] 0.68, 95% confidence interval [CI]
0.48–0.96). The clinical success rate was significantly higher among patients treated with
linezolid (adjusted HR 1.25, 95% CI 1.07–1.47). Comparable findings were observed in the
subgroup analyses.
3
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Conclusion: Individual clinical outcomes were similar among patients treated for MRSA
pneumonia with linezolid compared with vancomycin. A significantly higher rate of the
composite outcome of clinical success was observed, however, among patients treated with
linezolid compared with vancomycin.
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Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of pneumonia, which
is concerning because hospital-acquired pneumonia and ventilator-associated pneumonia
(VAP) caused by MRSA are associated with significant morbidity and mortality.1-3 For more than
50 years, the glycopetide antibiotic vancomycin has been considered the standard of care for
MRSA infections.4,5 Unfortunately, vancomycin may be a suboptimal therapeutic option because
of increasing minimum inhibitory concentrations among MRSA strains, poor penetration into
alveolar fluid, and high clinical failure rates.6-12 These limitations have led to the need for
additional therapeutic options.
Currently, vancomycin and linezolid are the only agents with activity against MRSA that
are approved for the treatment of nosocomial pneumonia in the United States and Europe. Thus
far, studies comparing the efficacy of these two drugs for the treatment of pneumonia have
demonstrated conflicting results. Although some studies have shown benefits for linezolid
treatment compared with vancomycin,13,14 many have found that the two drugs to have
equivalent efficacy.15-19 A recent, prospective, randomized controlled trial of culture-confirmed
MRSA nosocomial pneumonia showed benefits for linezolid over vancomycin for clinical
success, but no significant differences in mortality.20 Limitations of these studies, specifically
their methodological and statistical approaches, have been noted in multiple commentaries.21-28
These randomized trials provide important comparative efficacy data; however, they may
not reflect the effectiveness of these agents in real-world clinical practice. MRSA pneumonia is
a complex disease with significant morbidity and mortality; therefore, evaluating real-world
effectiveness in treating this disease is essential. Thus, we sought to quantify the effectiveness
of linezolid compared with vancomycin on clinical outcomes for the treatment of MRSA
pneumonia in a national Veterans Affairs (VA) cohort.
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Methods
The study design and methods were defined a priori in the study protocol, which was reviewed
and approved by the Institutional Review Board and Research and Development Committee of
the Providence Veterans Affairs Medical Center (Providence, RI).
Data Sources
The Veterans Health Administration has used an electronic medical record system since 1999.
Our study included national standardized databases capturing the following data relevant to
patient care: International Classification of Diseases, Ninth Revision (ICD-9) diagnostic and
procedure codes, pharmacy records (for prescriptions), laboratory tests and select laboratory
results, mortality, and patients’ vital signs.29,30
Patient Population and Study Design
We conducted a retrospective cohort study of adults (aged ≥ 18 years) admitted to VA hospitals
between January 1, 2002, and September 30, 2010, with an ICD-9 code for MRSA (038.12,
041.12, 482.42, V09.0) and pneumonia (482.40-482.42, 482.49, 482.89, 482.9, 484.8, 485-486,
510.0, 510.9, 513.0-513.1). Those patients who initiated and received at least 3 days of
continuous intravenous vancomycin or intravenous or oral linezolid therapy while in the hospital
were included in the analysis. Initiation in the hospital setting was defined as the absence of
linezolid or vancomycin therapy in the 7 days prior to starting therapy during the hospital
admission. Patients who died or were discharged within 3 days of treatment initiation, were
given vancomycin or linezolid in the nursing home, or were exposed to more than 2 consecutive
days of another antibiotic therapy with anti-MRSA activity (clindamycin, daptomycin,
doxycycline, linezolid, minocycline, tigecycline, trimethoprim-sulfamethoxazole, vancomycin) in
the 3 days before treatment initiation or during treatment with linezolid or vancomycin were
excluded. Only the first admission within the study period meeting all inclusion and exclusion
criteria was included.
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To validate our selection criteria for the study population, we conducted several
subgroup analyses. From the overall cohort, we identified a validated microbiology-confirmed
MRSA subgroup and clinical subgroup. To validate the MRSA and pneumonia diagnosis codes,
a manual electronic chart review on a random sample of 10% of all patients was completed. The
validated population included patients with an MRSA-positive culture from a suitable sputum
culture (<10 squamous epithelial cells and ≥25 leukocytes, or taken by an invasive technique
such as bronchoalveolar lavage) and patients from medical centers that achieved an average
validation of 80%. The clinical subgroup included patients with one of the following clinical
factors between admission day and treatment initiation: presence of a chest radiograph,
elevated body temperature (≥100.4°F), or elevated white blood cell count (≥ 10 x 103/mm3).
Definitions of Outcomes
The primary outcome measure was time to death (all-cause mortality) occurring within 30 days
of treatment initiation. Secondary outcomes included time to each of the following events:
therapy change, hospital discharge, intensive care unit (ICU) discharge, intubation, 30-day
readmission, 30-day MRSA reinfection, and clinical success as defined below. Date of therapy
initiation was used to define the index date of treatment. Time to therapy change, hospital
discharge, ICU discharge, and intubation were calculated from the index date to the event date
for each outcome. Postdischarge outcomes, including 30-day readmission and 30-day MRSA
reinfection, were calculated in the 30 days after hospital discharge. Therapy change was
defined as the discontinuation of linezolid or vancomycin and initiation of a different agent with
activity against MRSA. As such, therapy change could have included switching from linezolid to
vancomycin, switching from vancomycin to linezolid, or switching from either linezolid or
vancomycin to another anti-MRSA antibiotic (listed above). Switching an antibiotic from
intravenous to oral route was not considered a therapy change. Clinical rationale for therapy
change was not ascertained. Transfer out of the ICU was assessed among patients initiating

7

8
linezolid or vancomycin therapy in the ICU. For all time-dependent variables, we censored
patients on their date of death (if death occurred) or December 31, 2010, whichever occurred
sooner.
Clinical success was a composite outcome defined as discharge from the hospital or
ICU by day 14 after treatment initiation in the absence of death, therapy change, or intubation
by day 14. Nonsuccess was defined as therapy change, intubation, ICU admission, discharge
and readmission, or death between treatment initiation and day 14. Patients not meeting either
definition were excluded. Day 14 was chosen to replicate the average end-of-treatment time
frame from existing linezolid and vancomycin clinical trials.15,16,20 Sensitivity analyses evaluated
an alternate definition of clinical success excluding therapy change.

Statistical Analysis
Between-group differences were assessed using χ2 or Fisher exact tests for categorical
variables and the t-test or Wilcoxon rank sum test for continuous variables as appropriate.
Propensity scores were derived from unconditional logistic regression models. Time-to-event
analyses were conducted with Cox proportional hazards regression models. Adjustment was
achieved by controlling for propensity score quintiles. The propensity adjusted–Cox proportional
hazards regression models were used to quantify the effect of linezolid compared with
vancomycin treatment for MRSA pneumonia on the primary and secondary outcomes. A hazard
ratio (HR) greater than 1 indicates a higher probability of the event occurring in the linezolid
group compared with the reference vancomycin group. In terms of our study outcomes, HRs
greater than 1 would represent a higher mortality rate, decreased length of stay (LOS), or higher
readmission rate among patients treated with linezolid. All analyses were performed by using
SAS statistical software, version 9.1.3 (SAS Institute Inc., Cary, NC).
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Results
We identified 5271 patients who met our inclusion criteria, of whom 328 (6.2%) were treated
with linezolid and 4943 (93.8%) with vancomycin. The mean patient age was 69 years in both
treatment groups (Table 1). The majority of patients in both groups were white men. Several
statistically significant differences in frequency of comorbidities, including renal disease, cancer,
and dialysis, were observed between treatment groups. Geographic region of facility and
infections in the year prior to admission were characteristics that varied significantly between
the linezolid and vancomycin groups (Table 2). Although a number of baseline variables differed
significantly between the treatment groups, balance was achieved within propensity score
quintiles. The propensity score controlled for a number of patient demographics and
comorbidities present during the MRSA pneumonia admission, as well as medical history in the
year prior to the MRSA pneumonia admission. Several treatment-related characteristics were
also controlled for, including time to treatment initiation, year of treatment initiation, hospital unit
at treatment initiation, and treating specialty at initiation.
In the overall cohort, the 30-day mortality rate was 20.8% (19.5% linezolid vs 20.9%
vancomycin, p=0.56). Time to 30-day mortality did not vary significantly between treatment
groups (adjusted HR 0.91, 95% CI 0.70–1.17) (Table 3). A significantly lower rate of therapy
change, specifically discontinuation of linezolid or vancomycin and initiation of a different antiMRSA agent, among linezolid-treated patients was observed in the adjusted model (HR 0.68,
95% CI 0.48–0.96). Rates of hospital discharge, ICU discharge, intubation, 30-day MRSA
reinfection, and 30-day readmission did not differ significantly in either the unadjusted or
adjusted analyses. The mean ± SD time to discharge was 19.7 ± 24.4 days among linezolidtreated patients versus 20.3 ± 26.5 days among vancomycin-treated patients. Comparable
findings were observed in the validated and clinical subgroups. The clinical success rate was
significantly higher among patients treated with linezolid in the overall cohort, as well as in the
validated and clinical subgroups, as shown in Table 4: overall cohort (adjusted HR 1.25, 95% CI
9
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1.07–1.47), validated subgroup (adjusted HR 1.46, 95% CI 1.13–1.87), and clinical subgroup
(adjusted HR 1.25, 95% CI 1.03–1.52).

In subgroup analyses of the overall cohort, no associations between treatment group
and any of the study outcomes were observed among patients with renal insufficiency. Among
obese patients in the overall cohort (123 patients in the linezolid group, 2068 patients in the
vancomycin group), the rate of clinical success was significantly higher for linezolid-treated
patients in the unadjusted (HR 1.57, 95% CI 1.07-2.31) and adjusted (HR 1.77, 95% CI 1.18–
2.64) analyses. In sensitivity analyses of the overall cohort excluding therapy change from the
definition of success, linezolid was still associated with a higher rate of clinical success (179
patients in the linezolid group, 2632 patients in the vancomycin group; unadjusted HR 1.19,
95% CI 1.02-1.38; adjusted HR 1.18, 95% CI 1.01-1.37).
Discussion
We assessed the real-world effectiveness of linezolid compared with vancomycin in the
treatment of MRSA pneumonia in a large cohort of patients admitted to VA facilities nationally.
No significant differences were observed in the primary outcome measure, time to 30-day
mortality. These results regarding mortality are similar to findings from a pneumonia subset
analysis in a large national cohort study of veterans with MRSA infections.30 In addition, these
results are congruent with a recent clinical trial comparing linezolid with vancomycin for the
treatment of culture-confirmed MRSA pneumonia, in which no significant difference was
observed in mortality at 60 days (linezolid 15.7% vs vancomycin 17.0%).20
In our study, linezolid was associated with greater clinical success, a composite outcome
measure, compared with vancomycin. Our definition of clinical success was defined a priori
based on recently published clinical trials.15,16,20 Several clinical trials have demonstrated greater
clinical success with linezolid; however, the definitions of success varied among trials and
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compared with our study.13,14,20 Further, clinical success was determined by clinical judgment in
those trials rather than by objective criteria as in our study.
Previous retrospective infectious disease studies have developed definitions of clinical
success or failure based on available data, such as clinical, pharmacological, microbiological,
and laboratory measures.31-34 However, there is no consensus in the literature regarding the
definition of clinical success, particularly regarding the time of evaluation and specific
parameters to include in the measure.31-34 The clinical success definition we used in our study is
an algorithm based on objective criteria derived from the individual outcomes collected
(mortality, discharge, intubation, therapy change, readmission). Our sensitivity analyses of an
alternate definition of success, which removed therapy change as a parameter, revealed similar
findings, although to a lower magnitude (overall HR 1.25; excluding therapy change, HR 1.18),
of an association between linezolid and clinical success. In addition to traditional outcome
measures, such as mortality, length of stay, and pharmacoeconomics, it is useful to develop
outcome measures that are clinically or microbiologically based to assess differences between
groups and to assist in clinical decision making. As the prevalence of retrospective clinical
studies increase, it is likely that these measures will evolve and be validated over time.31
We did not observe an association between linezolid treatment and a higher discharge
rate for MRSA pneumonia, and thus mean LOS was comparable between treatment groups
(linezolid 19.7 days, vancomycin 20.3 days). This finding differs from an earlier national MRSA
cohort study, in which linezolid treatment was associated with a shorter LOS.30 In general,
evidence from randomized studies demonstrates a shorter LOS with linezolid treatment.35,36
However, these studies included patients with other types of infections, such as complicated
skin and soft tissue infections. MRSA pneumonia is a complicated infection with lengthy
recommended treatment durations of up to 21 days, depending on the extent of the infection,37
so it may have been less likely that we would observe differences in LOS and discharge rates in
our study than in studies of other infection types.
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In our retrospective cohort study, linezolid treatment was associated with a lower rate of
therapy change compared with vancomycin treatment in the adjusted overall analysis. Limited
data have been published on differences in therapy change with different agents. However, in
randomized trials, rates of discontinuation of linezolid or vancomycin were comparable to our
findings.15,16,19 It is possible that patients receiving intravenous vancomycin may have been
switched to a different antibiotic with an oral option as they were being prepared for discharge.
Comparable rates of time to ICU discharge, intubation, 30-day MRSA reinfection, and
30-day readmission were found between treatment groups in our study. In contrast, a
prospective, open-label trial found a nonsignificant trend favoring decreased length of ICU stay
with linezolid treatment; however, this trial limited inclusion to patients with MRSA VAP.38 In
retrospective studies, comparable rates of intubation and readmission rates have been found
with linezolid compared with vancomycin treatment.30,39 Few studies report readmission and
reinfection rates due to short follow-up periods.
Our study has several limitations. The retrospective design is associated with a number
of limitations, including that ICD-9 coding practices may vary among institutions and affect the
accuracy of our findings. In addition, there is discordance with ICD-9 coding and cultureconfirmed MRSA pneumonia infection,40 thereby leading to a potential misclassification. It is
likely our study did not capture all MRSA pneumonia infections due to missing codes for MRSA.
Because of the complexity of obtaining microbiologic data for this study, validation of ICD-9
codes of MRSA pneumonia was performed in a 10% patient sample. In addition, we had no
control over culture collection. Of the patients randomly selected for validation, 29% were
nonevaluable because no sputum samples were taken. This indicates treatment initiation for
suspected MRSA pneumonia, based on clinical signs and symptoms, without ever collecting a
sputum culture, which is why we also included a clinical subgroup in our analyses. In the
clinical subgroup, results of the chest radiographs were not available in the databases used.
However, patients in the clinical subgroup had to meet all inclusion criteria for the overall cohort
12
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in addition to having a chest radiograph between admission and initiation of treatment or one of
the other clinical symptoms (elevated body temperature or elevated white blood cell count).
Our study is further limited in that we did not evaluate success in all patients since we
excluded those not meeting the definition of success or nonsuccess by day 14 after treatment
initiation (linezolid 29.6%, vancomycin 29.2%). It is not known whether vancomycin dosing was
optimized among patients included in this study because trough levels were not available for
evaluation. Although balance was achieved within propensity score quintiles, there is the
potential for residual confounding by unobserved covariates. Finally, the generalizability of our
study may be limited to the VA population.
Conclusion
Our retrospective national cohort study demonstrated similar survival, LOS, readmission,
and reinfection rates for patients with MRSA pneumonia treated with linezolid or vancomycin.
Linezolid treatment was associated with a significantly higher rate of the composite outcome of
clinical success than vancomycin. These real-world clinical data support the results of previous
studies and further the understanding of MRSA pneumonia treatment.
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Table 1. Demographics and Comorbid Conditions by Treatment Group

Age (years)

69.1 ± 12.5

Vancomycin Group (n =
4943)
69.1 ± 12.7

Male sex

323 (98.5)

4844 (98.0)

White

266 (81.1)

3945 (79.8)

Other or unknown

62 (18.9)

998 (20.2)

2.8 ± 2.3

2.7 ± 2.3

140 (42.7)

2113 (42.7)

Renal disease

83 (25.3)

728 (14.7)

Diabetes mellitus

93 (28.4)

1547 (31.3)

Heart failure

86 (26.2)

1201 (24.3)

Coronary heart disease

83 (25.3)

1120 (22.7)

45 (13.7)

945 (19.1)

Dialysisa

36 (11.0)

183 (3.7)

Obesity

15 (4.6)

141 (2.9)

Amputation

4 (1.2)

90 (1.8)

Para- or quadriplegia

21 (6.4)

291 (5.9)

Cerebrovascular disease

32 (9.8)

485 (9.8)

Peripheral vascular disease

20 (6.1)

336 (6.8)

Moderate or severe liver disease

6 (1.8)

93 (1.9)

HIV/AIDS

7 (2.1)

55 (1.1)

Bacteremiaa

52 (15.9)

1037 (21.0)

Skin infection

88 (26.8)

1213 (24.5)

9 (2.7)

178 (3.6)

Covariate

Linezolid Group (n = 328)

Race-

Charlson comorbidity index
Comorbid conditions
Chronic respiratory disease
a

Cancer

a

Surgical site infection

Data are mean ± SD or no. (%) of patients.
HIV = human immunodeficiency virus; AIDS = acquired immunodeficiency syndrome.
a
p<0.05 for the comparison between treatment groups.
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Table 2. Healthcare and Antibiotic Exposures and Hospitalization-Related Characteristics
by Treatment Group
Vancomycin Group (n =
Linezolid Group (n = 328)
Variable
4943)
Previous hospitalization in the last
227 (69.2)
3368 (68.1)
year
Previous hospitalization in the last
186 (56.7)
2530 (51.2)
90 days
Previous surgery in the last year
78 (23.8)
993 (20.1)
Previous anti-MRSA antibiotics in
154 (47.0)
2181 (44.1)
the last 90 days
Previous immunosuppressants in
8 (2.4)
131 (2.7)
the last 90 days
Infections during the previous year
Pneumonia

143 (43.6)

1722 (34.8)

Chronic skin ulcer

73 (22.3)

909 (18.4)

Bacteremiaa

36 (11.0)

303 (6.1)

MRSA

59 (18.0)

574 (11.6)

Pseudomonas aeruginosa

23 (7.0)

232 (4.7)

121 (36.9)

1771 (35.8)

Hospital

30 (9.1)

303 (6.1)

Nursing home

32 (9.8)

612 (12.4)

137 (41.8)

1998 (40.4)

21 (6.4)

280 (5.7)

170 (51.8)

2665 (53.9)

142 (43.3)

1878 (38.0)

14 (4.3)

183 (3.7)

172 (52.4)

2882 (58.3)

Northa

39 (11.9)

629 (12.7)

South

178 (54.3)

2278 (46.1)

Midwest

65 (19.8)

953 (19.3)

West

46 (14.0)

1083 (21.9)

Admission source
Home

Hospital unit at treatment initiation
Intensive care
Surgery
General medicine
Treating specialty
Intensive care
Surgery
General medicine
Region of facility

Data are no. (%) of patients.
MRSA = methicillin-resistant Staphylococcus aureus.
a
p<0.05 for the comparison between treatment groups.
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Table 3. Outcomes in Overall Cohort: Linezolid Compared with Vancomycin
Unadjusted Hazard Ratio (CI)
(linezolid group [n=328] vs
vancomycin group [n=4942])

Adjusted Hazard Ratio (CI)
(linezolid group [n=328] vs
vancomycin group [n=4942])

30-day mortality

0.93 (0.72–1.20)

0.91 (0.70–1.17)

Discharge

1.02 (0.90–1.15)

1.04 (0.92–1.18)

Therapy change

0.75 (0.53–1.05)

0.68 (0.48–0.96)

ICU discharge

1.03 (0.86–1.25)

1.03 (0.85–1.24)

ICU transfer

0.65 (0.39–1.09)

0.70 (0.42–1.18)

Intubation

0.96 (0.68–1.37)

0.97 (0.68–1.38)

30-day MRSA reinfection

0.89 (0.54–1.48)

0.93 (0.56–1.56)

30-day readmission

0.88 (0.68–1.13)

0.89 (0.69–1.15)

Outcome

CI = confidence interval; ICU = intensive care unit; MRSA = methicillin-resistant Staphylococcus aureus.
The propensity score for the overall cohort was derived from an unconditional logistic regression model controlling for
race, admission source, region of facility, hospital unit at treatment initiation, treating specialty, chronic renal disease,
diabetes mellitus, cancer, metastatic cancer, myocardial infarction, cardiac arrhythmia, obesity, depression,
bacteremia, endocarditis, gram-negative infection, Escherichia coli infection, Streptococcus infection, complication of
implant or graft, complication of surgery or medical care, amputation procedure, dialysis, intravenous line, urinary
catheter, number of inpatient procedures, time to therapy initiation, year, MRSA pneumonia diagnosis code, inpatient
admission in the previous 30 days, procedure in the previous 180 days, previous metastatic cancer, previous
coronary heart disease, previous congestive heart failure, previous human immunodeficiency virus infection, previous
peripheral vascular disease, previous plegia, previous rheumatoid arthritis or connective tissue disease, previous
peptic ulcer, previous weight loss, previous depression, previous drug abuse, previous S. aureus infection, previous
pneumonia, previous bacteremia, previous surgical site infection, previous skin abscess, previous chronic ulcer,
previous infective arthritis, previous vancomycin-resistant Enterococcus infection, previous E. coli infection, and
previous intravenous line.
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Table 4. Clinical Success of Linezolid Compared with Vancomycin
Cohort

Unadjusted Hazard
Ratio (CI)

Adjusted Hazard Ratio
(CI)

1.24 (1.06–1.45)

1.25 (1.07–1.47)

1.40 (1.10–1.78)

1.46 (1.13–1.87)

1.19 (0.98–1.44)

1.25 (1.03–1.52)

Overall cohort (linezolid group [n=231]
vs vancomycin group [n=3500])
Validated subgroup (linezolid group
[n= 97] vs vancomycin group
[n=1411])
Clinical subgroup (linezolid group
[n=165] vs vancomycin group
[n=2536])
CI = confidence interval.
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